Angiogenesis 2021: Imaging among the focal points for February 12 agenda

January 28, 2021
Lynda Charters

Three sessions cover the range from clinical updates for imaging to emerging therapies for non-exudative AMD.

The Bascom Palmer Eye Institute continues its annual Angiogenesis, Exudation, and Degeneration 2021 meeting this February in a virtual setting across 2 days from Friday, Feb. 12, through Saturday, Feb. 13.

Here is an overview of the planned offerings for Friday, which includes 3 sessions.

Following opening remarks by the program co-directors—Philip J. Rosenfeld, MD, PhD; Harry W. Flynn Jr., MD; and Thomas A. Albini, MD—the presentations will commence at 8 am Eastern.

Session I: Imaging Normal and Non-Exudative AMD Eyes includes the following:

  • Histopathology of Basal Laminar Deposits and Bruch’s Membrane in AMD
    Christine A. Curcio, PhD
  • Ultra-High Resolution SD-OCT in Normal Aging and AMD, James G. Fujimoto, PhD
  • Quantitative Measurements of 3D Choroid and Choriocapillaris Using SS-OCT, Ruikang (Ricky) Wang, PhD
  • Computational Modelling for Assessing OCT Biomarkers of Geographic Atrophy Growth, Eric M. Moult, BSc
  • The Status of the Choriocapillaris in Nascent GA, Robyn Guymer, MBBS, PhD, FRANZCO, FAHMS
  • Rate of Progression of iRORA to cRORA in AMD, David Sarraf, MD
  • En Face OCT Imaging Simplifies the Detection of Pre-cRORA Lesions
    Philip J. Rosenfeld, MD, PhD

Session II: Imaging Eyes With Exudative AMD will begin at 9:30 am Eastern and feature:

  • OCTA Biomarkers for CNV Secondary to AMD, Seung-Young Yu, MD
  • Detection of Exudative AMD at Earliest Onset Yields New Information on Lesion Morphology, Usha Chakravarthy, MD
  • Multimodal Imaging Features and Clinical Relevance of Subretinal Lipid Globules, K. Bailey Freund, MD
  • Home OCT Based Management of Neovascular AMD, Anat Loewenstein, MD

Session III: Emerging Therapies for Non-Exudative AMD, beginning at 10:30 am Eastern, is the final session of the day and will include:

  • Results of a Phase 1/2 Study on Gene Therapy for the Treatment of Geographic Atrophy, Nadia K. Waheed, MD, MPH
  • C5 Inhibition with Avacincaptad Pegol for the Treatment of Geographic Atrophy, Pravin U. Dugel, MD
  • Inhibition of Complement C3 in Geographic Atrophy with NGM621: Phase 1 Study Results, Charles C. Wykoff, MD, PhD
  • C3 Inhibition with Pegcetacoplan for the Treatment of GA in AMD, Cedric G. Francois, MD, PhD
  • Is it Valid to Use CAM OCT Criteria for Macular Atrophy in Interventional Non-Neovascular and Neovascular AMD Clinical Trials?, Glenn J. Jaffe, MD
  • Impact of Pegcetocoplan on Progression of Nascent Atrophy in AMD, SriniVas R. Sadda, MD
  • Update on Elamipretide for the Treatment of AMD , Jeffrey S. Heier, MD

Attendees will reconvene at 8 am on Saturday, Feb. 13, for the second day of the program.

To attend the virtual meeting, registration must be received by Tuesday, February 9, at noon EST. Conference registration is $100 and the number of registrants is limited.